Do neighborhood-level disparities in breast cancer–specific survival remain after accounting for individual, tumor, and treatment characteristics?

The role of neighborhood-level disparities in determining shorter breast cancer-specific survival.

Janssen submits sBLA to FDA for NSCLC combination therapy

Janssen is seeking FDA approval for the combination therapy of RYBREVANT plus chemotherapy for NSCLC. Credit: user:ekem / commons.wikimedia.org. The Janssen Pharmaceutical Companies of Johnson &

August 28, 2023

GLP-1-based polyagonists: A promising weight loss alternative to bariatric surgery

Researchers highlight the unprecedented success of GLP-1-based multi-receptor drugs in achieving substantial weight loss and improved health outcomes, potentially replacing bariatric surgery for obesity treatment.

July 29, 2024

Abbott CEO talks diabetes market, device pricing at J.P. Morgan conference

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Abbott CEO Robert Ford expects the company

January 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.